Evidence map›Paper›PMID 40998803›Full record

ArticleNature communications2025

Targeting prostaglandin E

Romina Nassini, Lorenzo Landini, Matilde Marini, Martina Chieca, Daniel Souza Monteiro de Araújo, Marco Montini, Pasquale Pensieri, Vittorio Donato Abruzzese, Gaetano De Siena, Jin Zhang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Engineering Nanoscale Drug Delivery Systems for Pain.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Romina NassiniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-9223-8395
Lorenzo LandiniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-3933-2497
Matilde MariniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-2199-2905
Martina ChiecaDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-0247-9938
Daniel Souza Monteiro de AraújoDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0003-1115-725X
Marco MontiniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Medical Genetics Unit, University of Florence, Florence, Italy.
Pasquale PensieriDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Vittorio Donato AbruzzeseDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Gaetano De SienaDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Jin ZhangDepartment of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
Elisa BellantoniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Vincenzo De GiorgiDepartment of Health Sciences, Dermatology Section, University of Florence, Florence, Italy.
Antonia RomitelliDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Giulia BrancoliniFloNext srl, Florence, Italy.ORCID http://orcid.org/0009-0008-9269-8253
Raquel TonelloDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY, USA.
Chloe J PeachDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY, USA.
Alessandra MastricciDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0009-0009-3755-8802
Irene ScuffiDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
Martina TesiDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.ORCID http://orcid.org/0009-0004-2352-4277
Dane D JensenDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0001-6540-2375
Brian L SchmidtDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2409-8984
Nigel W BunnettDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0003-3367-0644
Francesco De Logu *Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy. francesco.delogu@unifi.it.ORCID http://orcid.org/0000-0001-8360-6929
Pierangelo Geppetti *Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy. pierangelo.geppetti@unifi.it.ORCID http://orcid.org/0000-0003-3797-8371

Funding

Live-cell Activity Architecture in CancerR35CA197622 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jin Zhang · 2015 to 2026
$11.2M
Mechanisms of Compartmentalized cAMP SignalingR01DK073368 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jin Zhang · 2006 to 2026
$7.6M
Targeting Endosomal Receptors for Treatment of Chronic PainR01DE029951 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2020 to 2024
$4.7M
Protease/PAR2/TRPV4 Axis and Oral Cancer PainR01DE026806 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2022
$3.9M
Endosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4M
Trafficking-Dependent Signaling of Pain by Protease-Activated ReceptorsR01DK118971 · NIDDK · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2021
$3.2M
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 835286NCI NIH HHS R35 CA197622NIDCR NIH HHS R01 DE026806NIDCR NIH HHS R01 DE029951NIDDK NIH HHS R01 DK073368NIDDK NIH HHS R01 DK118971NINDS NIH HHS R01 NS102722
6 · The paper itself

Abstract

Analgesia by non-steroidal anti-inflammatory drugs (NSAIDs) is ascribed to inhibition of prostaglandin (PG) biosynthesis and ensuing inflammation. However, NSAIDs have life-threatening side effects, and inhibition of inflammation delays pain resolution. Decoupling the mechanisms underlying PG-evoked pain vs. protective inflammation would facilitate pain treatment. Herein, we reveal that selective silencing of the PGE

Indexed as

InflammationPainReceptors, Prostaglandin E, EP2 SubtypeSchwann CellsAdenylyl CyclasesAnimalsAnti-Inflammatory Agents, Non-SteroidalCyclic AMPCyclic AMP-Dependent Protein KinasesDinoprostoneHumansMaleMiceMice, Inbred C57BLSignal TransductionAdenylyl CyclasesAnti-Inflammatory Agents, Non-SteroidalCyclic AMPCyclic AMP-Dependent Protein KinasesDinoprostoneReceptors, Prostaglandin E, EP2 Subtype

Identifiers

PMID40998803
PMCPMC12462433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.